Management of HIV Based on CD4 Count

Antiretroviral Therapy Initiation

The American Journal of Kidney Diseases recommends that antiretroviral therapy (ART) should be initiated in all HIV-infected patients regardless of CD4 count, representing a fundamental shift from historical CD4-based thresholds and is now the standard of care across all major guidelines 1, 2
The American College of Physicians suggests a universal treatment approach, starting ART immediately upon HIV diagnosis, irrespective of CD4 count, to reduce morbidity, mortality, and HIV transmission risk 1, 3
For patients with CD4 counts >500 cells/μL, the American Journal of Kidney Diseases recommends initiating ART immediately, based on large trials demonstrating reduced rates of severe illness with immediate treatment 1
The Infectious Diseases Society of America recommends initiating ART regardless of CD4 count for patients with HIV-related kidney disease, adjusted for degree of kidney function 1

The Clinical Infectious Diseases journal suggests that CD4 counts should be monitored every 3-4 months to assess urgency for ART initiation and determine need for opportunistic infection prophylaxis 4, 5
For patients on suppressive ART with CD4 counts well above opportunistic infection thresholds, the Clinical Infectious Diseases journal recommends monitoring can be reduced to every 6-12 months unless clinical status changes 4, 5

The Centers for Disease Control and Prevention recommends initiating Pneumocystis jirovecii pneumonia (PCP) prophylaxis for patients with CD4 <200 cells/μL (or CD4% <14%) 2, 6
The Infectious Diseases Society of America suggests considering screening for disseminated Mycobacterium avium complex (MAC) and cryptococcal infection in selected patients with CD4 <50 cells/μL, though routine screening is not recommended 4, 5

The Clinical Infectious Diseases journal recommends obtaining a complete blood count with differential, comprehensive metabolic panel with calculated creatinine clearance, fasting lipid profile, HLA B*5701 testing, tuberculosis screening, hepatitis B and C screening, and baseline chest radiograph if tuberculosis screening is positive upon HIV diagnosis 2, 4, 5, 7

The American Journal of Kidney Diseases emphasizes the importance of earlier treatment initiation, as higher CD4 counts at ART initiation are associated with better long-term outcomes 1

The therapeutic goal in HIV infection is restoration and preservation of immune function, with a progressive increase in CD4 count after initiating antiretroviral therapy (ART)【8】.
Clinical CD4 thresholds (rather than a fixed “target”) are used to define the risk of opportunistic infections and the need for prophylaxis【8】【9】.
Historically, a CD4 count > 350 cells/µL was the threshold for starting ART, but current guidelines recommend universal treatment irrespective of CD4 level【8】【9】.
At the start of care, a baseline CD4 count together with the CD4 % should be obtained as part of the initial evaluation【10】【11】【12】.
Because CD4 counts can vary substantially during acute illness, many experts advise obtaining two baseline CD4 measurements before making treatment‑initiation decisions【13】【14】.
Approximate CD4 % values can aid interpretation: a CD4 count of ~200 cells/µL corresponds to roughly 14 % and a count of ~500 cells/µL to about 29 %【10】【11】【13】【14】.

The Infectious Diseases Society of America (IDSA) guidelines state explicitly that routine measurement of CD8 count and the CD4/CD8 ratio is unnecessary for clinical decision‑making, because these results are not used to guide therapeutic management【10】【11】【12】【13】【14】.

The IDSA statements are guideline recommendations (strong recommendation) based on expert consensus and systematic review of the literature (clinical practice guideline level).

All bullet points are supported by the cited references.